Tu1789 – Treatment Response to Ustekinumab and Vedolizumab in Inflammatory Bowel Disease: the Predictive Role of Gut Microbiota

Abstract Background Several studies have highlighted the role of host–microbiome interactions in the pathogenesis of inflammatory bowel disease (IBD), resulting in an increasing amount of data mainly focusing on Western patients. Because of the increasing prevalence of IBD in newly industrialized countries such as those in Asia, the Middle East, and South America, there is mounting interest in elucidating the gut microbiota of these populations. We present a comprehensive analysis of several IBD-related biomarkers and gut microbiota profiles and functions of a unique population of patients with IBD and healthy patients from Kazan (Republic of Tatarstan, Russia). Methods Blood and fecal IBD biomarkers, serum cytokines, and fecal short-chain fatty acid (SCFA) content were profiled. Finally, fecal microbiota composition was analyzed by 16S and whole-genome shotgun sequencing. Results Fecal microbiota whole-genome sequencing confirmed the presence of classic IBD dysbiotic features at the phylum level, with increased abundance of Proteobacteria, Actinobacteria, and Fusobacteria and decreased abundance of Firmicutes, Bacteroidetes, and Verrucomicrobia. At the genus level, the abundance of both fermentative (SCFA-producing and hydrogen (H2)-releasing) and hydrogenotrophic (H2-consuming) microbes was affected in patients with IBD. This imbalance was confirmed by the decreased abundance of SCFA species in the feces of patients with IBD and the change in anaerobic index, which mirrors the redox status of the intestine. Conclusions Our analyses highlighted how IBD-related dysbiotic microbiota—which are generally mainly linked to SCFA imbalance—may affect other important metabolic pathways, such as H2 metabolism, that are critical for host physiology and disease development.

Download Full-text

Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients

Journal of Clinical Laboratory Analysis ◽

10.1002/jcla.24130 ◽

2022 ◽

Author(s):

Zhigang Wu ◽

Yingyan Bi

Keyword(s):

Inflammatory Bowel Disease ◽

Treatment Response ◽

Bowel Disease ◽

Disease Surveillance ◽

Potential Role ◽

Response Prediction ◽

Inflammatory Bowel ◽

Treatment Response Prediction

Download Full-text

Whole Food–Based Approaches to Modulating Gut Microbiota and Associated Diseases

Annual Review of Food Science and Technology ◽

10.1146/annurev-food-111519-014337 ◽

2020 ◽

Vol 11 (1) ◽

pp. 119-143 ◽

Cited By ~ 6

Author(s):

Yanhui Han ◽

Hang Xiao

Keyword(s):

Inflammatory Bowel Disease ◽

Gut Microbiota ◽

Bowel Disease ◽

Fruits And Vegetables ◽

Beneficial Effects ◽

Associated Diseases ◽

Associated Functions ◽

Inflammatory Bowel ◽

Whole Foods

Intake of whole foods, such as fruits and vegetables, may confer health benefits to the host. The beneficial effects of fruits and vegetables were mainly attributed to their richness in polyphenols and microbiota-accessible carbohydrates (MACs). Components in fruits and vegetables modulate composition and associated functions of the gut microbiota, whereas gut microbiota can transform components in fruits and vegetables to produce metabolites that are bioactive and important for health. The progression of multiple diseases, such as obesity and inflammatory bowel disease, is associated with diet and gut microbiota. Although the exact causality between these diseases and specific members of gut microbiota has not been well characterized, accumulating evidence supported the role of fruits and vegetables in modulating gut microbiota and decreasing the risks of microbiota-associated diseases. This review summarizes the latest findings on the effects of whole fruits and vegetables on gut microbiota and associated diseases.

Download Full-text

Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years?

World Journal of Gastroenterology ◽

10.3748/wjg.v20.i5.1192 ◽

2014 ◽

Vol 20 (5) ◽

pp. 1192 ◽

Cited By ~ 177

Author(s):

Georgina L Hold

Keyword(s):

Inflammatory Bowel Disease ◽

Gut Microbiota ◽

Bowel Disease ◽

Disease Pathogenesis ◽

The Past ◽

Inflammatory Bowel

Download Full-text

Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome

Pathogens ◽

10.3390/pathogens8030126 ◽

2019 ◽

Vol 8 (3) ◽

pp. 126 ◽

Cited By ~ 52

Author(s):

Israr Khan ◽

Naeem Ullah ◽

Lajia Zha ◽

Yanrui Bai ◽

Ashiq Khan ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Gut Microbiota ◽

Bowel Disease ◽

Intestinal Inflammation ◽

Current Knowledge ◽

Pathological Condition ◽

Gut Flora ◽

Core Microbiome ◽

Inflammatory Bowel

Inflammatory bowel disease (IBD) is a chronic complex inflammatory gut pathological condition, examples of which include Crohn’s disease (CD) and ulcerative colitis (UC), which is associated with significant morbidity. Although the etiology of IBD is unknown, gut microbiota alteration (dysbiosis) is considered a novel factor involved in the pathogenesis of IBD. The gut microbiota acts as a metabolic organ and contributes to human health by performing various physiological functions; deviation in the gut flora composition is involved in various disease pathologies, including IBD. This review aims to summarize the current knowledge of gut microbiota alteration in IBD and how this contributes to intestinal inflammation, as well as explore the potential role of gut microbiota-based treatment approaches for the prevention and treatment of IBD. The current literature has clearly demonstrated a perturbation of the gut microbiota in IBD patients and mice colitis models, but a clear causal link of cause and effect has not yet been presented. In addition, gut microbiota-based therapeutic approaches have also shown good evidence of their effects in the amelioration of colitis in animal models (mice) and IBD patients, which indicates that gut flora might be a new promising therapeutic target for the treatment of IBD. However, insufficient data and confusing results from previous studies have led to a failure to define a core microbiome associated with IBD and the hidden mechanism of pathogenesis, which suggests that well-designed randomized control trials and mouse models are required for further research. In addition, a better understanding of this ecosystem will also determine the role of prebiotics and probiotics as therapeutic agents in the management of IBD.

Download Full-text

Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease

Mediators of Inflammation ◽

10.1155/2016/9890141 ◽

2016 ◽

Vol 2016 ◽

pp. 1-11 ◽

Cited By ~ 15

Author(s):

Phillips-Farfán Bryan ◽

Carvajal Karla ◽

Medina-Torres Edgar Alejandro ◽

Espinosa-Padilla Sara Elva ◽

Fabrias Gemma ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Immune Response ◽

Immune System ◽

Gut Microbiota ◽

Bowel Disease ◽

Therapeutic Agents ◽

Intestinal Cells ◽

Intestinal Immunity ◽

Inflammatory Bowel

Inflammatory bowel disease (IBD) describes different illnesses characterized by chronic inflammation of the gastrointestinal tract. Although the pathogenic mechanisms leading to IBD are poorly understood, immune system disturbances likely underlie its development. Sphingolipids (SLs) have been identified as important players and promising therapeutic targets to control inflammation in IBD. Interestingly, it seems that microorganisms of the normal gut microbiota and probiotics are involved in sphingolipid function. However, there is a great need to investigate the role of SLs as intermediates in the crosstalk between intestinal immunity and microorganisms. This review focuses on recent investigations that describe some mechanisms involved in the regulation of cytokine profiles by SLs. We also describe the importance of gut microbiota in providing signaling molecules that favor the communication between resident bacteria and intestinal cells. This, in turn, modulates the immune response in the bowel and likely in other peripheral organs. The potential of SLs and gut microbiota as targets or therapeutic agents for IBD is also discussed.

Download Full-text